Rani Therapeutics Holdings Inc (NASDAQ: RANI) on Monday, plunged -4.22% from the previous trading day, before settling in for the closing price of $1.66. Within the past 52 weeks, RANI’s price has moved between $1.60 and $8.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 83.82% over the past five years. The company achieved an average annual earnings per share of 7.89%. With a float of $22.83 million, this company’s outstanding shares have now reached $29.81 million.
Let’s look at the performance matrix of the company that is accounted for 140 employees. In terms of profitability, gross margin is 73.45%, operating margin of -1883.31%, and the pretax margin is -1996.98%.
Rani Therapeutics Holdings Inc (RANI) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Rani Therapeutics Holdings Inc is 31.46%, while institutional ownership is 14.32%. The most recent insider transaction that took place on Dec 13 ’24, was worth 29,993. In this transaction Chief Business Officer of this company bought 17,960 shares at a rate of $1.67, taking the stock ownership to the 17,960 shares. Before that another transaction happened on Dec 09 ’24, when Company’s Chief Executive Officer bought 10,296 for $1.94, making the entire transaction worth $19,974. This insider now owns 494,751 shares in total.
Rani Therapeutics Holdings Inc (RANI) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 7.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.40% during the next five years compared to 0.28% growth over the previous five years of trading.
Rani Therapeutics Holdings Inc (NASDAQ: RANI) Trading Performance Indicators
Rani Therapeutics Holdings Inc (RANI) is currently performing well based on its current performance indicators. A quick ratio of 1.60 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.06, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.01 in one year’s time.
Technical Analysis of Rani Therapeutics Holdings Inc (RANI)
Rani Therapeutics Holdings Inc (NASDAQ: RANI) saw its 5-day average volume 0.55 million, a positive change from its year-to-date volume of 0.55 million. As of the previous 9 days, the stock’s Stochastic %D was 7.15%. Additionally, its Average True Range was 0.14.
During the past 100 days, Rani Therapeutics Holdings Inc’s (RANI) raw stochastic average was set at 0.46%, which indicates a significant decrease from 1.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.19% in the past 14 days, which was lower than the 124.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.2259, while its 200-day Moving Average is $3.4751. Nevertheless, the first resistance level for the watch stands at $1.6800 in the near term. At $1.7700, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.8200. If the price goes on to break the first support level at $1.5400, it is likely to go to the next support level at $1.4900. The third support level lies at $1.4000 if the price breaches the second support level.
Rani Therapeutics Holdings Inc (NASDAQ: RANI) Key Stats
Market capitalization of the company is 87.11 million based on 57,289K outstanding shares. Right now, sales total 0 K and income totals -33,970 K. The company made 0 K in profit during its latest quarter, and -6,780 K in sales during its previous quarter.
